Pharmacy evidence record · researched 2026-08-20
Aequita Pharmacy LLC
Washington's official release identifies Aequita as compounding GLP-1s such as semaglutide.
Washington's official release identifies Aequita as compounding GLP-1s such as tirzepatide.
Product evidence does not establish current availability.
Regulatory compliance
A pathway label describes which federal rules apply — it is not a quality claim.
Section 503A
Aequita held a Washington pharmacy license and compounded patient-specific GLP-1 products, but Washington imposed a Limited Stop Service in March 2025 prohibiting compounding and distribution until resolved.
Section 503B
not found in current fda registry check
Telehealth providers
Clinic Scout links a provider only when an explicit source names the relationship.
Regulatory history
FDA warning-letter, compounding-action/current 503B-registry and Washington regulator sources were checked. Washington actions were verified; no FDA warning letter was found in the bounded search.
Washington Pharmacy Quality Assurance Commission · 2025-03-13
The commission prohibited Aequita from compounding and from dispensing, delivering, or distributing compounded products. Allegations included untrained/unqualified staff performing sterile compounding, inadequate supervision, and failures to follow sterile-compounding procedures.
Status not statedWashington Pharmacy Quality Assurance Commission · 2025-07
Washington reported that the commission and Aequita entered an agreed order after multiple inspections.
Status not statedNo Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.
What this record verifies for you
Each line traces to a citation in the source list below — read the exact captured wording before relying on it.
No superiority claim is made for review volume, ratings, or patient sentiment.
The notice of immediate Limited Stop Service alleges that Aequita, which compounds Glucagon-like peptide-1s (GLP-1s) such as Semaglutide and Tirzepatide, failed to develop and implement a commission-approved plan of correction ... Aequita cannot compound and cannot dispense, deliver, or distribute compounded products in Washington state until the Limited Stop Service is resolved.
In July 2025 the Pharmacy Quality Assurance Commission and Aequita Pharmacy LLC entered an agreed order.
Updated as of 8/18/2026 ... This table lists the outsourcing facilities that have submitted registration information that has been determined to be complete by the data lock date for the latest weekly update of the table.
GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 3 dated first-party or regulator citation(s), 2 regulatory/action record(s), and 5 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.
Weekly price watch
One useful comparison each week. No spam, no sold lists, and you can unsubscribe anytime.